Key facts
- Visterra’s last known valuation is $430.0M (Aug 2018).
- It has raised $630K across 1 recorded rounds; the latest was Early Stage VC ($34.2M) in May 2012.
- Notable investors include AB Private Credit Investors.
- Visterra has filed 4 Form Ds with the SEC since 2010, most recently Dec 2013 ($34.2M sold to 16 investors).
- Status: Acquired/Merged (Operating Subsidiary).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Visterra
Funding rounds
1 roundsAbout Visterra
Operator of a clinical-stage biopharmaceutical company designed to treat infectious diseases caused by organisms. The company designs and engineers antibody-based biological products for the treatment of non-infectious diseases that are not being adequately addressed, enabling healthcare providers and researchers to seek the significant unmet need for effective therapies.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2008
- Employees
- 150
- Website
- visterrainc.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Visterra doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Visterra shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Visterra in its N-PORT filings yet. We sweep new filings monthly.